ID: ALA297524

Max Phase: Preclinical

Molecular Formula: C20H29NO3

Molecular Weight: 331.46

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)[C@H]1CCC2C3CNC4=CC(=O)CC[C@]4(C)C3CC[C@@]21C

Standard InChI:  InChI=1S/C20H29NO3/c1-19-9-7-15-13(14(19)4-5-16(19)18(23)24-3)11-21-17-10-12(22)6-8-20(15,17)2/h10,13-16,21H,4-9,11H2,1-3H3/t13?,14?,15?,16-,19+,20-/m1/s1

Standard InChI Key:  ZJOMBWSBLZDZAK-YANZXGQTSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 331.46

Molecular Weight (Monoisotopic): 331.2147

AlogP: 3.07

#Rotatable Bonds: 1

Polar Surface Area: 55.40

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa:

CX LogP: 2.47

CX LogD: 2.47

Aromatic Rings: 0

Heavy Atoms: 24

QED Weighted: 0.75

Np Likeness Score: 1.77

References

1. Kenny B, Ballard S, Blagg J, Fox D..  (1997)  Pharmacological options in the treatment of benign prostatic hyperplasia.,  40  (9): [PMID:9135028] [10.1021/jm960697s]

2. Frye SV, Haffner CD, Maloney PR, Mook RA, Dorsey GF, Hiner RN, Cribbs CM, Wheeler TN, Ray JA, Andrews RC..  (1994)  6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase.,  37  (15): [PMID:8057283] [10.1021/jm00041a014]

3. Frye SV, Haffner CD, Maloney PR, Mook RA, Dorsey GF, Hiner RN, Batchelor KW, Bramson HN, Stuart JD, Schweiker SL..  (1993)  6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5 alpha-reductase.,  36  (26): [PMID:8277514] [10.1021/jm00078a022]

Source

Source(1):

• Scientific Literature